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Abstract. The advent of recent advances in near-infrared laser diodes and fast electro-optic detection has spawned a new research
field of diagnostic spectroscopy and imaging based on targeting and reporting exogenous fluorescent agents. This review seeks
to concisely address the physics, instrumentation, advancements in tomography, and near-infrared fluorescent contrast agent
development that promises selective and specific molecular targeting of diseased tissues. As an example of one area of the
field, recent work focusing on pharmacokinetic analysis of fluorophores targeting the epidermal growth factor receptor (EGFR)
is presented in a human breast cancer xenograft mouse model to demonstrate specificity of molecularly targeted contrast agents.
Finally, a critical evaluation of the limitations and the opportunities for future translation of fluorescence-enhanced optical imaging
of deep tissues is presented.
1. Introduction: Fluorescence-enhanced optical
imaging
Near-infrared (NIR) light of 700–900 nm can pen-
etrate several centimeters of tissue without the harm-
ful radiation effects of gamma rays, x-rays, or ultra-
violet light. As a result, over the past several years
considerable interest has been focused on the integra-
tion of optics and medicine, principally on the de-
velopment of clinically relevant diagnostic imaging
techniques. Because of the low absorbance of en-
dogenous chromophores such as oxy- and deoxyhe-
moglobin, melanin, and fat, NIR light can propagate
significant distances via multiple scattering, enabling
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imaging of deep (> 1 cm) tissues. The ability to detect
late-stage breast cancers using tomographic imaging
based on the intrinsic contrast provided by hemoglobin
absorption as a result of tumor-initiated angiogenesis
has been demonstrated [1]. Unfortunately, the neces-
sity of angiogenesis-mediated absorption contrast lim-
its the potential of NIR optical imaging because small
lesions possess insufficient vascularity for endogenous
optical contrast. Hence, NIR optical techniques can
be expanded through the use of exogenous contrast-
enhancing agents. Exogenous fluorophores have been
shown to provide superior enhanced contrast when
time-dependent measurements of light propagation are
employed [2,3]. Furthermore, new and future oppor-
tunities for molecular-based diagnostic imaging are af-
forded when optical imaging techniques are coupled
with NIR-excitable fluorescent contrast agents devel-
oped for in vivo targeting and reporting of cancer and
other tissue abnormalities.
In this review, we focus upon the measurement
approaches, promises for tomography, and advances
in fluorescent contrast-agent development that are di-
rected toward molecular targeting of disease. We fur-
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ther demonstrate that the specific binding or uptake of
fluorescent agents directly impacts the pharmacokinet-
ics of agent distribution, which can be evaluated read-
ily with NIR imaging techniques. Finally, since NIR-
excitable probes provide the promise for deep-tissue lo-
calization in clinical applications, we discuss the trans-
lation of fluorescent dye development to pertinent di-
agnostic applications.
1.1. NIR measurement approaches
There are three distinct methods for monitoring the
propagation of NIR light and the emission of gener-
ated fluorescent light. These methods are continuous
wave (CW), time-domain photon migration (TDPM),
and frequency-domain photon migration (FDPM). The
earliest and simplest methods of measuring NIR light
interaction with tissue involve intensity-based or CW
techniques. CW techniques generally involve measur-
ing the spatial distribution of light intensity at the tissue
surface resulting from illumination by a source of con-
stant intensity. CW techniques may be used to measure
NIR fluorescence from exogenous contrast agents with
a point or area light source at the excitation wavelength
incident on the tissue surface. The collection of the
fluorescence re-emitted from the tissue surface occurs
through a point or area detector that discriminates the
re-emitted fluorescence from the excitation light. Be-
cause the excitation light fluence (which represents the
amount of light in terms of its local concentration [pho-
tons/volume] times the speed of light [length/time], or
alternatively in terms of a flux [photons/area/time]) ex-
ponentially attenuates as it travels from the tissue sur-
face, the excitation fluence always remains greatest at
the tissue surface. Furthermore, the amount of gen-
erated fluorescence at any given position within the
tissue is proportional to the product of the local fluo-
rophore concentration and the local excitation fluence.
As a result, a low concentration of fluorophore at or
near the tissue surface can produce the bulk of the de-
tected signal emitted and collected in CW techniques.
A consequence of CW methods is that the signal from
a deeper embedded target containing a high concen-
tration of fluorophore may be masked easily by a very
low concentration of fluorophore at or near the tissue
surface. As discussed below, methods that measure the
time-dependence of light propagation may escape this
limitation.
In addition to measuring the spatial distribution
of light intensity, time-dependent measurement ap-
proaches also are capable of measuring the temporal
distribution of the detected light. Time-resolved tech-
niques employ an excitation light source whose inten-
sity varies with time. TDPM techniques make use of
ultra-short (femtosecond-picosecond) light pulses and
detectors that either are fast, time-gated, or single-
photon counting devices. A light pulse is delivered
to the tissue, which, as a result of multiple scattering,
broadens with nanosecond “time-of-flight” and atten-
uates as it propagates through the tissue. In the pres-
ence of an NIR-excitable fluorophore, a fluorescence
pulse is generated within the tissue that increasingly
is broadened and attenuated owing to the fluorescence
decay kinetics of the fluorophore. Because the region
of highest excitation light fluence is not constant and
propagates away from the tissue surface with time, the
spatial location of the generated fluorescent pulse also
varies, resulting in the deeper origin of fluorescent sig-
nals re-emitted at the tissue surface. As a result, as long
as the lifetime or the average time for relaxation of the
fluorophore is less than or comparable to the “time-of-
flight” associated with light propagation, the detected
fluorescence may, as a function of time, originate from
various depths within the tissue in time-dependent mea-
surement methods [4].
An alternative time-dependent measurement method-
ology, which is directly related to TDPM through the
Fourier transform, is known as FDPM. In this approach,
a light source that is sinusoidally intensity-modulated
at radio frequencies is used to launch photons into the
tissue. Typically, modulation frequencies range from
30–200 MHz. As the intensity-modulated light (also
referred to as a “photon density wave”) propagates
through the tissue, its amplitude is attenuated and it
experiences a phase-lag relative to the incident light.
In the presence of an NIR fluorophore, the intensity-
modulated excitation fluence results in a fluorescent
“photon density wave” or intensity-modulated emis-
sion fluence that is further amplitude-attenuated and
phase-delayed, owing to the fluorescent decay kinetics
of the dye in its current environment [5]. The phase-lag
and amplitude-attenuation of the detected fluorescent
photon density wave, measured relative to the incident
light wave using a fast detector or array of detectors, are
pronounced owing to the fluorophore’s decay kinetics.
As a result, fluorescence-enhanced FDPM may be used
to exploit the fluorescent relaxation process to improve
contrast in the phase-lag and amplitude-attenuation of
the detected signal.
Similar to TDPM, the excitation light fluence in
FDPM also varies in time and space, and the region of
highest excitation fluence is not located consistently at
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the tissue surface. Consequently, as long as the product
of the fluorophore lifetime and modulation frequency
is less than one, the detected fluorescence may orig-
inate from deep within the tissue, even in the pres-
ence of background dye [6]. Another important fea-
ture of FDPM measurements concerns their inherent
insensitivity to ambient light. Because the amplitude
of the detected fluorescent signal is unaffected by non-
modulated ambient light, FDPM enables greater sen-
sitivity and depth of penetration than do conventional
CW techniques [7,8].
1.2. NIR fluorescence-enhanced optical imaging
The preponderance of NIR fluorescence imaging
studies conducted to date have focused on CW mea-
surements in a rodent model using either an array of
point illumination and an array of point collection of
generated fluorescence, or area illumination with an
expanded excitation beam and collection of the gener-
ated fluorescence using an array detector, or a simple
charge-coupled device (CCD) camera (for review see
reference [8]). The use of a point source of illumination
light and point collection of generated fluorescent light
is the most inefficient means to image an entire tissue
but is advantageous since current tomographic algo-
rithms focus on reconstruction of optical properties in
the volume of tissues “sampled” between the incident
illumination and collection points on the surface of a
tissue (see below). The excitation light that originates
from a point on the tissue surface and that ultimately
is detected at another point on the tissue surface has
sampled a finite volume [9]. The detected fluorescence
also is constrained to within this “sampling volume”.
Consequently, a number of measurements of point il-
lumination/point collection pairs are required to sam-
ple the entire tissue, and tomographic reconstruction
is required. In contrast, employing an expanded beam
to deliver excitation light results in a larger sampling
volume and, hence, in fluorescence re-emitted from a
greater volume of tissue. When time-dependent mea-
surements are employed, the re-emitted fluorescence
may originate from a greater depth from the tissue sur-
face, as described in the earlier section.
Many investigators have employed CW measure-
ments of targeting fluorophores in rodents utilizing
whole-animal illumination with an expanded excita-
tion beam and a simple CCD camera to collect the re-
emitted fluorescence. In their development work on
fluorescent contrast agents discussed below, Achilefu
and coworkers [10–13], Bugaj and coworkers [14], Za-
heer et al. [15], and Becker et al. [16], employed CW
techniques with area illumination and collection in their
studies of targeting dye-peptide conjugates. Owing to
factors such as non-uniformity of the illuminating ex-
panded excitation beam and the inhomogeneity of en-
dogenous absorption and scattering properties of ani-
mal tissues, direct and accurate quantitation of target-
ing dye accumulation within tissues was not possible.
Tomographic reconstruction of dye concentration also
is not possible from these studies, as described further
in the next section. Nonetheless, qualitative assess-
ment of the targeting capacity of developed dye-peptide
conjugates was made possible. Area illumination and
area detection has proven useful and valuable for small-
animal imaging for development of NIR fluorophores.
In studies of spontaneous canine mammary dis-
ease probed with area illumination using an expanded
and intensity-modulated excitation beam and area
collection of the intensity-modulated emission light,
Reynolds et al. [17] and Gurfinkel et al. [18] followed
the accumulation of non-specific and specific dyes in
the mammary chain and within regional lymph nodes.
Upon collecting the amplitude of the detected mod-
ulated fluorescent signal, the ambient non-modulated
light was rejected from the measurement, enabling data
collection under less than dark-room conditions. The
images of detected amplitude, average of detected am-
plitude, and phase delay across the surface of the il-
luminated tissue further showed the ability to localize
sub-surface lesions and regional lymph nodes as deep
as 1–3 cm. Owing to sub-second integration times
afforded by the use of a gain-modulated intensified
CCD camera [19,20], the calculation of the kinetics
of dye accumulation were enabled from the sequential
images, providing indication of the specificity of the
dyes employed. To date, the tomographic reconstruc-
tion of fluorescence from area illumination and area
collection has not been presented in the literature. In
addition, while time-dependent measurements such as
TDPM and FDPM measurements enable tomographic
recovery of fluorescence decay parameter maps [21],
to date recovery from experimental measurements has
not been demonstrated.
1.3. NIR fluorescence-enhanced optical tomography
The process of tomography involves conducting
measurements of the re-emitted excitation and emis-
sion light from the boundaries of tissue, using a math-
ematical model describing light propagation and flu-
orescence generation, and finally reconstructing the
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interior optical properties to delineate disease. To
date, researchers conducting studies on optical tomog-
raphy have employed the diffusion model of light
propagation, which requires that the detected signals
be randomized in their direction and that only multi-
ple scattered light is collected (for review see refer-
ences [8,22,23]). As a general rule of thumb, light that
has been scattered and collected after it has traveled at
least 10 times the mean-free scattering length can be
considered to be multiply scattered. Most biological
applications in which the mean free-scattering length is
on the order of millimeters require that measurements
be conducted between points of incident illumination
and collection that are separated by at least one cen-
timeter. Consequently, the tomographic reconstruc-
tion of optical images from small-rodent models us-
ing the diffusion approximation may be questionable,
and more appropriate methods using the full radiative
transfer equation as pioneered by Hielschler et al. [24]
are required. Therefore, tomographic reconstruction of
fluorescence-enhanced imaging using small animals is
not directly translatable to the clinically relevant vol-
umes because the physics of light propagation differ
and prevent a convenient “scale up” methodology.
Nonetheless, there have been several experimental
demonstrations of tomographic reconstruction of ab-
sorptive cross section owing to fluorophore. Ntziachris-
tos and coworkers demonstrated NIR fluorescence-
enhanced tomography from CW measurements in a
mouse model with targeting and reporting agents [25].
The study involved CW measurements between cir-
cumferential points of excitation illumination and flu-
orescence collection around a 74-cm3 cylinder con-
taining a mouse and index-matching fluid. In con-
trast, using FDPM measurements, Lee and Sevick-
Muraca [26] and Hawrysz et al. [27] conducted trans-
mittance and reflectance measurements across a 260-
cm3 tissue-mimicking phantom using point illumina-
tion of excitation light and point collection of fluores-
cence to reconstruct images of heterogeneities. More
recently, this work has been extended using unique
Bayesian tomographic algorithms [28] to hemispheri-
cal phantoms of approximately 1000-cm3 volume [29].
The most clinically relevant application of area excita-
tion illumination and area fluorescence detection over
a wide field of view has not been the subject of tomo-
graphic algorithm development to date but was demon-
strated experimentally by Roy [30]. The translation
of NIR fluorescence-enhancedoptical imaging requires
the continued tomographic algorithm development in
geometries that are pertinent to clinical imaging.
2. Limitations to fluorescent-enhanced optical
imaging and tomography
In contrast to nuclear and small-animal biolumi-
nescence imaging, fluorescence-enhanced imaging re-
quires incident illumination with excitation light to re-
cover an NIR fluorescent signal at the tissue surface.
Frequently, the fluorescence signals emitted at a partic-
ular location on the tissue surface can be several orders
of magnitude smaller than are the excitation signals
emitted from the same location and comparable to the
ambient light under non-dark-room conditions. In the
latter case, the FDPM system of discriminating signals
that are modulated at MHz modulation frequencies en-
abled reduction in the noise floor for fluorescent sig-
nals [7]. The former case is more problematic. Unfor-
tunately, discrimination of fluorescent from excitation
light signals often is accomplished via optical filters
whose excitation light rejection capabilities are insuf-
ficient for resolving the fluorescent signals from small
quantities of dye. Whether FDPM or CW measure-
ments are employed, the limitation owing to excitation
light leakage limits the noise floor of the measurements.
For clinical translation, the excitation rejection capa-
bilities must be improved to image nanomolar to pico-
molar concentrations of fluorescence contrast agents at
significant tissue depths.
A limitation that has been overcome in tomographic
work using point illumination and point collection ge-
ometries, but not yet addressed in the literature for area
illumination and area collection, is the spatial variation
of the incident excitation source power [26,31]. This is
problematic especially for whole-body expanded beam
illumination of excitation light for recovery of fluores-
cence using CCD detection. Using a series of polar-
izers to segregate the specularly reflected component
of excitation light from the diffuse portion, Thomp-
son et al. showed that one can characterize the spa-
tial variation of an incident excitation light [32]. The
work shows that, on properly characterizing the spatial
variation of the incident excitation light illuminating
the surface of a tissue-mimicking phantom, diffusion
model-based prediction of the generated fluorescence
can match that measured experimentally using FDPM
techniques. This work paves the way for model-based
image reconstruction from area detection of fluores-
cence signals resulting from area illumination of exci-
tation light [30].
One approach to circumventing spatial variation
in excitation power, heterogeneity of tissue chro-
mophores, and variation in noise floor in small-animal
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imaging is to conduct rapid measurements (whether
CW measurements or amplitude measurements in
FDPM) to follow temporal change in fluorescent inten-
sity, from which pharmacokinetic parameters can be
recovered. Assuming that the spatial distribution of
excitation light and that tissue endogenous absorption
remains constant in time during the imaging procedure,
the map of pharmacokinetic parameters provides an in-
dication of specificity for the fluorescent contrast agent
in small-animal studies. This contribution provides an
illustration of the usefulness of pharmacokinetics in
studying a peptide-targeting paradigm directed to the
epidermal growth factor receptor (EGFR) that is over-
expressed in some cancers.
Before presenting this work, the following section re-
views the current status and development of fluorescent
contrast agents for molecular targeting of disease using
fluorescence- enhanced optical imaging approaches.
3. Current research in fluorescent dye
development
Characteristics important to consider in optimizing
imaging properties of NIR dyes include the follow-
ing: (1) the fluorophore should possess an excita-
tion/emission spectra with maxima in the NIR wave-
lengths (700–900 nm) to allow for minimal absorp-
tion by endogenous chromophores such as hemoglobin,
lipids, and water; (2) the fluorophore should possess a
high quantum yield; (3) the fluorophore should be sta-
ble chemically and optically; and (4) the fluorophore
should exhibit suitable pharmacological properties, in-
cluding a high specificity for the desired target and few
non-specific interactions. Over the last several years,
NIR fluorophores with optimal photochemical proper-
ties have been developed.
3.1. Indocyanine green
Of the heptamethine NIR fluorophores, the indolyl
(indo)cyanines show particular promise. Indocyanine
green dye (ICG) (Structure A, Figure 1) and its deriva-
tives remain the best candidates due to favorable ex-
citation and emission at 805 nm and 835 nm, respec-
tively, which occur at wavelengths where blood and
tissue are relatively transparent. Clinical use of ICG
was approved as early as 1956 (IC-GreenTM, Akorn,
Inc., Buffalo Grove, IL). The dye has maintained a re-
markably good safety profile since its introduction into
clinics. ICG provides optimal imaging of choroidal
circulation, making it an excellent adjunct to fluores-
cein angiography. ICG also has been used clinically
for monitoring cardiac output and for assessing hepatic
function [33,34]. Furthermore, ICG is highly bound to
plasma protein as compared with fluorescein dye (98%
versus 45%) and, as a result, does not leak from vessels
as readily (http://www.Akorn.com). Consequently, it is
used primarily as a blood-pool agent for NIR imaging.
In addition to its non-specificity, ICG undergoes a
well-documented aggregation process in aqueous me-
dia, resulting in a wavelength shift of the main ab-
sorbance peak and a concurrent loss of absorption and
fluorescence [35]. Therefore, there exists a need for
a novel composition that improves the dye stability in
solution, is simple to prepare, and, most importantly,
retains the high fluorescence yield in vivo. Rajagopalan
et al. reported non-covalent interaction of an anionic
polymer, sodium polyaspartate, with ICG that produced
an enhanced fluorescent stability of the dye in aqueous
solution [36]. When left in aqueous solution and kept
in clear bottles under normal laboratory lighting con-
ditions, ICG lost most of its fluorescence due to aggre-
gation. However, mixture of ICG with polyaspartate
resulted in a solution that retained strong fluorescence
even at day 24 under the same storage conditions [36].
Others have attempted to devise analogs of ICG with
improved physiochemical properties, and more impor-
tantly, to obtain NIR dyes with functional groups that
can be used readily to label biomolecules such as pep-
tides, proteins, drugs, and oligonucleotides.
3.2. Other fluorescent labeling agents for conjugation
Ito et al. reported the synthesis of ICG succinimidyl
ester (ICG-OSu) as an NIR-labeling dye in which one
of the sulfonyl groups in ICG was replaced by a car-
boxyl group (Structure B, Fig. 1) [37]. The method
was later extended to the preparation of ICG-acyl-1,3-
thiazolidine-2-thione (ICG-ATT) (Structure C, Fig. 1)
for the selective labeling of amines [38]. ATT re-
acted efficiently with amine but not with hydroxyl
and sulfhydryl groups. Unfortunately, these dyes suf-
fer poor water solubility [38]. Even after an addi-
tional sulfonate was introduced through the use of
N-dydroxysulfosuccinimide, the ICG-sulfo-OSu dye
still was not soluble enough to dissolve in water. In
the labeling reaction, ICG-sulfo-OSu was added to the
buffer solution of protein as DMSO solution [37]. As
expected of highly liposoluble ICG dyes, proteins la-
beled with ICG were not stable in phosphate-buffered
saline (PBS) solution due to dye-dye interaction and ag-
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Fig. 1. Structures of various fluorescent contrast agents employed in NIR optical imaging studies. A. ICG; B. ICG-Sulfo-Osu [37]; C.
ICG-ATT [38]; D. Cy5 [39]; E. Cy5.5 [40]; F. Heptamethine Cyanine Dye [41]; G. IRDye78 [42].
gregation. Furthermore, dye-dye interactions at high-
labeling densities led generally to fluorescence quench-
ing, limiting the brightness with labeled proteins and
loss of absorption over time [37].
CyDye fluors (Amersham Biosciences, Piscataway,
NJ) are one of the popular choices for NIR fluores-
cent labeling. Mujumdar et al. initially reported the
synthesis of amino-reactive cyanine dyes that contain
a negatively charged sulfonate group on the aromatic
nucleus of the indocyanine fluorophore [39]. These
sulfoindocyaninedyes are highly water-soluble and can
be used to prepare brightly fluorescent materials that
show low non-specific binding. Furthermore, the wave-
lengths of cyanine dyes can be tuned by altering the
heterocyclic nucleus and the number of double bonds
in the polymethine chain. Building upon their origi-
nal synthesis of cyanine dyes from indocyanine hete-
rocyclic nuclei [39], Mujumdar et al. introduced sul-
fonate groups at various positions on the benzindocya-
nine dye with the promise that benzindocyanine can
shift the absorbance 30 nm toward longer wavelengths
than the corresponding indocyanine dye [40]. It was
noted further that, to prevent dye-dye aggregation with
associated fluorescence quenching, it was necessary to
introduce two sulfonate groups on each of the benzin-
dolenine nuclei. The structures of Cy5 dye based on
indocyanine heterocyclic nucleus and Cy5.5 dye based
on benzindocyanine heterocyclic nucleus are shown in
Fig. 1 (Structure D & E).
Narayanan and Patonay reported a simple syn-
thetic procedure for heptamethine cyanine dyes through
the use of 2-chloro-1-formyl-3-(hydroxymethylene)
cyclohex-1-ene as an unsaturated bisaldehyde [41]. An
important feature of this method is that asymmetric
dyes derived from two different heterocycles may be
synthesized in a single pot due to better control of
the reaction rate. Another feature is that, in addition
to the activated alkyl side chain, the vinylic chlorine
on the cyclohexene bridgehead of the dye can be dis-
placed by nucleophilic substitution to introduce amine-
reactive functional groups (Structure F, Fig. 1) [41,42].
Compared to CyDye fluors, a major limitation of these
dyes is the lack of water solubility required to avoid
dye-dye interaction and non-specific binding. To in-
crease aqueous solubility of this series of heptame-
thine indocyanine dyes, polysulfonate groups were in-
troduced to both alkyl chains and indocyanine hetero-
cycles [43]. The resulting dye, termed IRDye78, now
is available commercially (LI-COR, Lincoln, NE) as an
N-hydroxysuccinimide ester of 3-(p-hydroxyphenyl)
propanoic acid substituted on the cyclohexene bridge-
head of the dye (Structure G, Fig. 1). Note that nu-
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cleophilic attack can occur at the cyclohexene bridge-
head, resulting in the displacement of the fluorophore
from the phenoxylpropionic acid group and the pro-
tein molecule attached to it, essentially decoupling the
fluorophore and ligand [43].
3.3. Targeting fluorescent probes
To achieve receptor localization and specific imag-
ing of cancer, fluorescent dyes have been attached to
various ligands. The benefit to such specific targeting
schemes is clear: the high selectivity and affinity of
receptor ligands result in a high signal-to-noise ratio
and also enable the use of low (picomolar to nanomo-
lar) concentrations of the compounds [16]. Most of
the published fluorescent probe studies are targeted at
cancers (at the tumor cells themselves, or at molecular
markers of the disease) to identify malignant lesions,
for defining tumor spread to adjacent tissues, and as a
guide for optimizing treatments of solid tumors.
3.3.1. Tumor targeting dye-antibody conjugates
Targeting fluorescent dyes for optical imaging was
first attempted by the direct conjugation of cyanine
dyes to monoclonal antibodies that are directed against
certain tumor-associated antigens [44–46]. Folli et al.
showed specific tumor targeting first using an anti-
carcinoembryonic antigen monoclonal antibody cou-
pled with fluorescein (anti-CEA mAb-fluorescein) [44]
and later using the monoclonal antibody E48 coupled
to indopentamethinecyanin (mAb E48-indocyanin) to
target squamous cell carcinomas in mice [45]. The
studies reported tumor localization by both conjugates
with tumor-to-normal tissue ratios of 10 and 8 for the
case of the mAb-fluorescein conjugate and the mAb-
indocyanin conjugate, respectively. Furthermore, the
mAb-indocyanin conjugate resulted in a clearly de-
tectable fluorescent signature due to its excitation and
emission wavelengths at 640 nm and 667 nm, re-
spectively; whereas the fluorescence from mAb E48-
fluorescein was detected only after removal of the
mouse skin due to fluorescein’s emission at lower wave-
lengths (∼500 nm) [45]. These results further demon-
strate that the efficiency of tumor immunophotodiagno-
sis can be improved by coupling to fluorochromes ab-
sorbing and emitting in the red or infrared wavelengths.
Ballou et al. prepared fluorophore conjugates of
the cyanine dyes Cy3, Cy5, and Cy5.5 and two
well-understood tumor-targeting antibodies; namely,
anti-SSEA-1, which localizes tumors that express the
SSEA-1 antigen, and antibody 9.2.27, which is directed
to a human melanoma antigen [46]. Compared to flu-
orescein, these dyes exhibit more favorable fluorescent
signatures, emitting in the red wavelengths (emission
maxima for Cy3, Cy5, and Cy5.5 occur at 575 nm,
675 nm, and 700 nm, respectively). In their studies,
mice were tail-vein injected with 10–100 µg of the
fluorophore-antibody conjugates and imaged using ei-
ther a cooled CCD or intensified video camera. The
resulting fluorescence images demonstrated that, al-
though Cy3-antibody conjugates targeted tumors, the
Cy5 and Cy5.5 conjugates were more effective in visu-
alizing the tumors, particularly in deeper tissue, again
due to their fluorescence at longer wavelengths. The
studies also showed that the conjugate-tumor interac-
tion was so effective that fluorescence still was visual-
ized from the tumor tissue five days after injection.
Additionally, it is well known that EGFR is over-
expressed in many types of cancer. Soukos et al. re-
port the use of an anti-EGFR monoclonal antibody to
target a diagnostic fluorescent dye, Cy5.5, and a pho-
tochemically active dye, chlorine6, for photodynamic
therapy in the hamster cheek pouch carcinogenesis
model [47]. Using a CCD camera and simple CW flu-
orescence imaging, they observed specific targeting of
the antibody-Cy5.5 conjugate and noted that the best
contrast between normal and carcinogen-treated cheek
pouches occurred between four and eight days after in-
jection [47]. Using the antibody-chlorine6 construct,
they were able to specifically target tumor cells and sub-
sequently perform photodynamic therapy to reduce the
size of the tumors. The results demonstrate the poten-
tial for development of immunophotodiagnosis as both
a diagnostic tool and a method for monitoring response
to photodynamic therapy. Together, these works gave
credence to and set the stage for the burgeoning field of
molecular-based optical imaging for disease diagnosis.
3.3.2. Tumor targeting dye-peptide conjugates
Although dye-antibody conjugates were a major
breakthrough in the field of optical imaging, several
unfavorable features were inherent in the approach.
Large biomolecules, such as antibodies, often would
elicit an adverse immunogenic reaction [48]. The long
plasma half-life of the antibodies also would result in
high background fluorescence and long blood clearance
times [12,48]. Additionally, the biomolecules often are
taken up preferentially by the liver [10]. Finally, for
the detection of solid tumors that require the diffusion
of contrast agents from the vasculature, the penetration
of large dye conjugates is unfavorable due to the net
positive pressure within the tumor [49]. As a result,
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researchers recently devised a viable alternative to the
dye-antibody conjugate. In this paradigm, the fluores-
cent dye is attached to a small bioactive peptide that
specifically targets over-expressed tumor receptors.
Making use of a simple CW optical imaging
system for in vivo fluorescence detection in a rat
model, Achilefu et al. and Bugaj et al. studied pep-
tide conjugates of the dye cypate, an ICG ana-
logue [10,12,14]. They demonstrated that the cypate
dye-octreotate peptide conjugates, designated cytate-1
and cytate-66, specifically target somatostatin receptor-
rich tumors and specifically bind to the sst2 recep-
tors through the octreotate peptide [10,12,14]. Fur-
thermore, they demonstrated that the cypate dye-
bombesin peptide conjugates,designated cybesin-1 and
cybesin-66, selectively target bombesin receptor-rich
tumors [10,12,14]. In a separate analysis, Becker
et al. used an intensified CCD camera to perform
in vivo imaging of mouse xenografts after injecting
the cyanine dye-peptide conjugate indotricarbocyanine
(ITTC)-octreotate. The study yielded similar high-
tumor specificity for the dye-peptide conjugate, with a
tumor fluorescence threefold higher than that of normal
tissue up to 24 hours after injection [16].
In our ongoing work, detailed in the following sec-
tion, we investigate the dye conjugate Cy5.5 bound to
epidermal growth factor (EGF; Cy5.5-EGF) for imag-
ing human breast cancer xenografts in nude mice. The
results suggest that, in addition to the fluorescence
contrast to differentiate tumor margins, monitoring the
time course of a dye’s uptake enables pharmacokinetic
modeling that, in turn, can be used to delineate tumor
from normal tissue when a specific contrast agent is
employed.
Methodologies that employ protein-dye conjugates
to target cell-surface receptors also have been inves-
tigated. Becker et al. investigated the use of macro-
molecules as carriers of a fluorescent contrast agent for
the optical imaging of human colon cancer xenografts
in nude mice [50]. In their study, they compared
two protein-dye conjugates; the first consisted of an
ITCC derivative covalently bound to transferrin (Tf-
ITTC); the second, ITCC bound to human serum albu-
min (HSA-ITTC). They reported that both compounds
induced increased fluorescence contrast of tumors in
vivo due to the accumulation of the macromolecules in
the solid tumors as a result of enhanced vascular per-
meability and ineffective lymphatic drainage of tumor
interstitium. However, the Tf-ITTC conjugate induced
a higher fluorescence contrast, perhaps due in part to
receptor-mediated internalization of the compound in
tumor cells [50].
Finally, in addition to small peptides and proteins,
researchers also have investigated the use of small
molecules as delivery vehicles for fluorescent dyes. Za-
heer et al. reported the use of a pamidronate-IRDye78
conjugate, termed Pam78, to specifically bind hydrox-
yapatite, the major mineral product of osteoblasts and
calcifying vascular cells [15]. In their study, a CCD
camera was used to acquire in vivo fluorescence images
following the intravenous injection of Pam78 in nude
mice. In addition to demonstrating that the dye conju-
gate could be used to visualize most of the bony struc-
tures of the animal, they directly compared the fluores-
cence images with radioscintigraphy, the current gold
standard for imaging hydroxyapatite. The fluorescence
images provided high sensitivity, a higher resolution,
and a shorter integration time (500 ms for fluorescence
imaging versus 30 minutes for radioscintigraphy) [15].
Their study further demonstrates the wide scope of ap-
plications possible with NIR fluorescence imaging.
3.4. Activatable probes
Other methodologies for targeting fluorescent dyes
to tumors have been proposed and investigated. Among
them are schemes involving acid and enzyme cleavable
conjugates of dye-biomolecules [51,52]. Weissleder et
al. conjugated Cy5.5 onto a graft copolymer consisting
of a poly-L-lysine backbone and methoxypolyethylene
glycol side chains [51]. The dye molecules were con-
jugated in close proximity to each other to quench flu-
orescence. However, following intravenous injection
into tumor-bearing nude mice, the fluorescent probe ac-
cumulated in the tumors due to its long circulation time
and permeability through neovasculature. An intratu-
moral fluorescent signal was generated by lysosomal
proteases that cleaved the macromolecule and released
previously quenched fluorophore. In vivo fluorescence
imaging determined a 12-fold increase in fluorescent
signal and allowed for the detection of submillimeter-
sized tumors [51].
Matrix metalloproteinase (MMP) activity is known
to play a key role in many diseases including cancer.
As a result, MMP inhibitors have been developed as
anti-cancer drugs. In a recent study, Bremer et al. de-
veloped an activatable fluorescent probe for sensing
MMP activity in vivo in tumor-bearing mice [53]. The
MMP-sensitive probe consisted of quenched NIR flu-
orophore (Cy5.5) conjugated to an MMP peptide sub-
strate and a graft copolymer of methoxy-polyethylene-
glycol-derivatized poly-L-lysine. The probe would flu-
oresce when MMP enzymes cleaved the peptide sub-
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strate and released previously quenched fluorophore.
The fluorescent probe was injected into mice exhibiting
the HT1080 human fibrosarcoma tumor model, which
exhibits high MMP production. Subsequent in vivo
imaging resulted in a significantly higher fluorescence
signal from HT1080-bearing mice compared with con-
trol mice with tumors devoid of MMP activity. Further-
more, Bremer et al. demonstrated that the fluorescent
probe could be used to image MMP inhibition in vivo.
Mice with HT1080 tumors were treated with prinoma-
stat, a potent MMP inhibitor, for two days and subse-
quently imaged. The images revealed that there was
significantly less MMP-fluorescent signal in treated tu-
mors compared to untreated tumors [53].
Activatable probes that do not fully quench could
be imaged best with time-dependent methods of NIR
imaging. Specificity of imaging could be enhanced
if temporal fluorescence decay parameters were tomo-
graphically reconstructed.
3.5. Pharmacokinetics of specific and non-specific
dye uptake
A means for detecting specificity of targeting probes
resides in the determination of pharmacokinetics ob-
tained directly from small-animal imaging of the spa-
tial and temporal distribution of fluorescent signals. In
previous work, we investigated the use of a modified
photodynamic agent, hexylpyropheophorbidemodified
with carotene (HPPH-car), and monitored the pharma-
cokinetics of dye uptake as a means to discriminate
tumor from normal tissue in vivo in a canine model
of mammary disease [18]. Unlike the case of non-
specific ICG dye, we found that pharmacokinetic pa-
rameter maps of HPPH-car were successfully able to
delineate tumor from normal tissue. We reasoned that
the contrast was a result of specific interactions be-
tween the carotene moiety and cell-surface low-density
lipoprotein receptors commonly over-expressed on tu-
mor cells. Furthermore, we concluded that pharma-
cokinetic modeling afforded a method for assessing
specific dye-tumor interactions in vivo.
4. Example: Model for peptide targeting of EGFR
as evidenced by pharmacokinetic analysis
Herein, as an example of the specificity imparted by
molecularly targeting a fluorescent agent, we present
results from ongoing work in which we compare the
pharmacokinetics of the cyanine dye-peptide conjugate
Cy5.5-EGF and the non-specific ICG to image human
breast cancer xenografts in nude mice.
4.1. Fluorescent contrast agents
ICG is available commercially from Sigma (St.
Louis, MO); Cy5.5 is available commercially from
Amersham Biosciences (Piscataway, NJ) as a mono-
functional N-hydroxysuccinimide ester. ICG was in-
jected as a free non-specific dye, whereas Cy5.5 was
conjugated to EGF (Sigma, St. Louis, MO) to target the
EGFR. EGF is a 51-amino acid peptide with a molec-
ular weight of approximately 6000 Daltons. The dye-
peptide conjugate was synthesized such that there were
two dye molecules per peptide. An ultraviolet/visible
light spectroscopy quantification of the peptide and dye
confirmed the 2:1 molar ratio. ICG was injected at a
concentration of 3 µM (300 µl injection), whereas the
dye-peptide conjugate was injected at a concentration
of 57 µM (300 µl injection) based on dye content.
4.2. Animal model
Four- to six-week-old female athymic nude mice
(nu/nu; 18–22 g) were purchased from Harlan Sprague
Dawley, Inc. (Indianapolis, IN), housed five per cage,
and fed by sterilized pelleted food (Harlan Sprague
Dawley, Inc., Indianapolis, IN) and sterilized water.
Animals were maintained in a specific pathogen-free
mouse colony in the department of veterinary medicine
(The University of Texas M.D. Anderson Cancer Cen-
ter, Houston, TX). The facility is accredited by the
American Association for Laboratory Animal Care,
and all experiments were performed in accordance with
the guidelines of the Institutional Animal Care and Use
Committee.
MDA-MB-468 breast tumor cells that express EGFR
were obtained from American Type Culture Col-
lection (ATCC, Rockville, MD) and were cultured
in DMEM/F12 supplemented with 10% fetal bovine
serum (FBS). Cells were maintained at 37◦C in a hu-
midified atmosphere of 5% CO2.
Tumor cells to be implanted into mice were harvested
near confluence by incubation with 0.05% trypsin-
EDTA. Cells were pelleted by centrifugation at 450 ×
g for five minutes and resuspended in sterile PBS. Cells
(2–3 × 106/animal) were implanted subcutaneously
into the chest region of the mice.
Prior to imaging, the mouse was anesthetized by a
single dose of 50 mg kg−1 bw Nembutal administered
via an intraperitoneal injection. A tail-vein catheter
was placed for the subsequent injections of fluorescent
contrast agents. Finally, the fluorescent contrast agent
was injected at the time of imaging. The same mouse
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was used to study both contrast agents. For each case,
the injection consisted of a 0.3-ml bolus delivered via
the tail-vein catheter. For the Cy5.5-EGF study, the in-
jected dose of contrast agent consisted of 17 nanomoles
of Cy5.5 (8.5 nanomoles of EGF) in saline, whereas
the delivered dose of ICG was 900 picomoles in saline.
4.3. In vivo fluorescence imaging
In vivo fluorescence images of the animal were ob-
tained every six seconds for approximately 24 min-
utes following injection of the contrast agent. A laser
beam from a 35-mW, 660-nm (70-mW, 785-nm) laser
diode served as the excitation source for the Cy5.5-
EGF (ICG) experiment. The beam was expanded with
a plano-convex lens to approximately 8-cm diameter
such that the beam irradiated nearly the entire ani-
mal. A 660-nm (785-nm) holographic band-rejection
(Kaiser Optical Systems, Inc., Ann Arbor, MI) and
710-nm (830-nm) narrow band interference (CVI Laser
Corporation, Albuquerque, NM) filters combined to
pass only the fluorescence originating from the Cy5.5-
EGF (ICG) dye. Sufficient spectral separation exists
between the excitation/emission spectra of Cy5.5-EGF
and ICG to permit imaging both dyes in the same ani-
mal. The spatially preserved fluorescent light was am-
plified using an 18-mm Gen 3 image intensifier tube
(model FS9910C, ITT Industries, Roanoke, VA). The
final fluorescent images were captured using a charge-
coupled device camera (model CH350, Photometrics,
Tucson, AZ) with an 800-msec exposure time. Image
acquisition was controlled by V++ software (Digital
Optics, Auckland, New Zealand). A schematic de-
picting the intensified charge-coupled device (ICCD)
fluorescence imaging system is presented in Fig. 2.
4.4. Data analysis
For each image, the fluorescent intensity was aver-
aged from two equally sized regions of interest (ROI)
approximately 50 mm2 in area; one ROI encircled an
area of tumor tissue and the second enclosed an area
of non-tumorous normal tissue (Fig. 3). The averaged
fluorescent intensity was plotted as a function of time.
For the ICG experiment, the time-dependent fluores-
cent intensity can be described by a double-exponential
four-parameter model [18]:



































(KB + K + η) (5)
KB = Kt + K0 (6)
η =
√
K2B − 2KBK + K2 + 4KtK. (7)
Kt,Ko, and K represent the rate constants describing
dye uptake and wash-out from the blood to tissue, from
the blood to other organs such as liver and kidney,
and from the tissue to the blood, respectively. CBo
represents the concentration of dye in the blood at time
of injection (t = 0), and w1 and w2 are weighting
factors that describe the contribution to the observed
fluorescent signal from dye in the tissue and dye in the
blood compartments, respectively.
Similarly, the Cy5.5-EGF time-dependent fluores-
cent intensity can be expressed via a single-exponential
three-parameter model [18]:












For the ICG experiment, the time-dependent fluores-
cent intensity was fitted to Eq. (1) to obtain estimates
of the pharmacokinetic parameters. Likewise, Eq. (8)
was used to fit Cy5.5-EGF fluorescence intensity and
obtain estimates of the respective parameters.
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Fig. 2. Experimental system used for in vivo fluorescence imaging of tumor-bearing nude mice.
4.5. Results
As expected, the injection of contrast agent (ICG and
Cy5.5-EGF) resulted in an immediate increase in the
fluorescence signal of the whole body. Not surpris-
ingly, in both cases the strongest fluorescent signal was
observed from the region of liver. Approximately equal
fluorescent signals were observed at all times post in-
jection of ICG from the tumor-containing ROI and the
ROI of normal tissue (Fig. 4). Unlike ICG, the fluores-
cent signal due to Cy5.5-EGF continually increased in
the tumor ROI, whereas it became relatively constant in
the normal tissue ROI after approximately 10 minutes
(Fig. 5). Furthermore, Figs 4 and 5 show the results of
the pharmacokinetic analysis on the ICG-fluorescence
data and Cy5.5-EGF- fluorescence data, respectively.
For the ICG-pharmacokineticmodel, it is difficult to as-
sign physical meaning to the pre-exponential parame-
ters; however, the exponential parameters α and β con-
veniently sum to Kt+Ko+K . Furthermore, the pre-
exponential parameters are signal-intensity-dependent,
whereas the exponential parameters are independent of
signal strength and, thus, depend only on the shape of
the intensity-versus-time curve. As a result, the sum
of α and β can serve as the metric by which to com-
pare contrast based on pharmacokinetic analysis. Con-
sequently, the sum of α and β in the tumor ROI dif-
fers by less than 15% from the value calculated in the
normal ROI (calculated using Eq. (11)). This result
and a qualitative inspection of the time-dependent fluo-
rescent intensity curves for both the tumor and normal
ROIs (Fig. 4) further substantiate our claim that dif-
Fig. 3. White light image of the mouse prior to injection of contrast
agent. The highlighted squares outline the regions of interest (ROIs)
used in the pharmacokinetic study. ROI 1 encloses an area of tumor
tissue and ROI 2 encloses an area of normal tissue.
ferentiation of tumor from normal tissue based on the
pharmacokinetics of ICG is futile.
% change in (α + β) or KB
between normal and tumor tissue = (11)[
1− [(α + β) or KB]tumor
[(α + β) or KB]normal
]
× 100
The results of the pharmacokinetic analysis of Cy5.5-
EGF data considerably differ from those for ICG.
The exponential parameter KB varies by approxi-
mately 80% between the tumor and normal ROIs
(from Eq. (11)). A qualitative inspection of the time-
dependent fluorescent intensity curves for the tumor
and normal ROIs confirms that different mechanisms
govern the observed pharmacokinetic trends. The re-
sults further corroborate the notion that pharmacoki-
netic analysis can be used to differentiate tumor from
normal tissue when a specific contrast agent is em-
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Fig. 4. Pharmacokinetics of ICG.
ployed. That is, the contrast agent must display selec-
tive and specific binding for the tumor cells.
5. Industrial and clinical applications for
NIR-fluorescence-enhanced optical imaging
In the foregoing sections, we attempted to provide a
balanced review of the developments and the potential
for molecular imaging with NIR-fluorescent probes. To
date, two distinct opportunities exist that have not been
translated fully into industrial or clinical application.
The first involves small-animal imaging,and the second
involves diagnostic imaging in the clinic.
The opportunity for quantitative small-animal imag-
ing using fluorescence opens significant benefits for
drug discovery in evaluating the efficacy of new agents
and their biodistribution. Currently, the safety and ef-
ficacy of new drugs are developed initially in studies
that involve serial sacrifice of small animals to pro-
vide baseline information on toxicity, biodistribution,
and bioavailability. The development of a small-animal
imaging system with tomographic reconstruction of
concentration of agent is imperative. To date, although
there is a plethora of studies that involve small-animal
imaging for fluorescent-contrast agent development,
the ability for accurate tomographic reconstruction has
not yet been developed adequately in the framework
of proper physics. Indeed, since these small animals
do not constitute significant volumes, the ability to use
fluorophores that excite and emit in the visible range
certainly is viable for purposes of drug discovery.
In contrast, NIR-excitable fluorescent probes are sig-
nificant and required for deep-tissue diagnostic imag-
ing in humans and possibly in the veterinary clinic.
Clinical opportunities possibly may exist where diag-
nostic nuclear imaging techniques are employed. Cer-
tainly, gamma imaging and positron emission tomog-
raphy (PET) have instrumental analogs in the measure-
ment methods and tomography approaches outlined
above for the evolving field of optical imaging. Yet,
to date, owing to the lack of any approved fluorescent
contrast agent for the indication of diagnostic fluores-
cent imaging, the feasibility of these methods remains
restricted to tissue-phantoms and has yet to be validated
in actual tissues.
Acknowledgements
The authors acknowledge the support of National In-
stitutes of Health grants (R01 EB00174,R01 CA67176)
and the State of Texas Advanced Technology Program.
M. Gurfinkel et al. / Near-infrared fluorescence optical imaging and tomography 119
Fig. 5. Pharmacokinetics of Cy5.5-EGF.
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